newsfilter
← Latest News
GlobeNewswire·

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company"), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments,